INCYTE CORP (INCY)
Data as of , from SEC Form 4 filings.
See up to 3 months of INCY. The 7-day demo opens the 1M and 3M ranges and puts INCY on your watchlist.
Start 7-day demoLatest INCY insider trades
About INCYTE CORP (INCY)
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
- WILMINGTON, DE
- 2,844
- 1993
- XNAS
INCY Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 21 | 124,481 | $15.01M |
| Grant or award | 34 | 680,342 | |
| Option exercise | 42 | 142,384 | |
INCY insider transactions (Form 4)
111139 Form 4 filings on record, the earliest from Oct 2, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Lee Heeson - Officer | Tax withholding / forfeiture | Common Stock | 463 footnote F1 | $117.14 | $54K | |
| ||||||
| BAKER BROS. ADVISORS LP - Director | Grant or award | Common Stock | 322 footnote F1 | $0.00 | - | |
| BAKER BROS. ADVISORS LP - Director | Grant or award | Common Stock | 322 footnote F1 | $0.00 | - | |
| ||||||
| Paul J. Clancy - Director | Grant or award | Common Stock | 203 | $121.35 | $25K | |
| Edmund Harrigan - Director | Grant or award | Common Stock | 206 | $121.35 | $25K | |
| David H. Gardner - Officer | Tax withholding / forfeiture | Common Stock | 920 footnote F1 | $126.93 | $117K | |
| ||||||
| Option exercise | Common Stock | 2,957 | $61.76 | $183K | ||
| Option exercise | Common Stock | 4,551 | $61.18 | $278K | ||
| Option exercise | Common Stock | 6,477 | $64.25 | $416K | ||
| Option exercise | Common Stock | 9,233 | $71.93 | $664K | ||
| Open-market sale | Common Stock | 9,233 | $120.50 | $1.11M | ||
| Open-market sale | Common Stock | 13,985 | $120.49 | $1.69M | ||
| Option exercise | Employee Stock Option (right to buy) | 2,957 | $0.00 | - | ||
| Option exercise | Employee Stock Option (right to buy) | 4,551 | $0.00 | - | ||
| Option exercise | Employee Stock Option (right to buy) | 6,477 | $0.00 | - | ||
| Option exercise | Employee Stock Option (right to buy) | 9,233 | $0.00 | - | ||
| Ramitpal K. Basi - Officer | Tax withholding / forfeiture | Common Stock | 504 footnote F1 | $129.72 | $65K | |
| ||||||
| Open-market sale | Common Stock | 10,801 | $125.56 | $1.36M | ||
| Open-market sale | Common Stock | 10,803 | $120.04 | $1.30M | ||
| Open-market sale | Common Stock | 10,640 | $122.69 | $1.31M | ||
| Option exercise | Common Stock | 2,207 | $106.47 | $235K | ||
| Open-market sale | Common Stock | 2,207 | $123.99 | $274K | ||
| Option exercise | Employee Stock Option (right to buy) | 2,207 | $0.00 | - | ||
| Open-market sale | Common Stock | 15,888 | $119.70 | $1.90M | ||
| Option exercise | Common Stock | 2,864 | $77.67 | $222K | ||
| Option exercise | Common Stock | 1,643 | $80.50 | $132K | ||
| Option exercise | Common Stock | 3,023 | $83.20 | $252K | ||
| Option exercise | Common Stock | 2,623 | $83.58 | $219K | ||
| Option exercise | Common Stock | 1,642 | $85.01 | $140K | ||
| Option exercise | Common Stock | 2,293 | $90.56 | $208K | ||
| Option exercise | Common Stock | 85 | $106.47 | $9K | ||
| Option exercise | Common Stock | 326 | $105.43 | $34K | ||
| Open-market sale | Common Stock | 14,661 | $119.46 | $1.75M | ||
| Open-market sale | Common Stock | 5,332 | $119.42 | $637K | ||
| Open-market sale | Common Stock | 2,187 | $119.47 | $261K | ||
| Open-market sale | Common Stock | 6,171 | $119.43 | $737K | ||
| Open-market sale | Common Stock | 4,695 | $119.39 | $561K | ||
| Open-market sale | Common Stock | 2,864 | $119.40 | $342K | ||
| Open-market sale | Common Stock | 1,643 | $119.51 | $196K | ||
| Open-market sale | Common Stock | 1,642 | $119.38 | $196K | ||
| Open-market sale | Common Stock | 85 | $122.19 | $10K | ||
| Open-market sale | Common Stock | 326 | $121.69 | $40K | ||
| Open-market sale | Common Stock | 2,293 | $119.41 | $274K | ||
| Option exercise | Common Stock | 6,055 | $105.43 | $638K | ||
| Option exercise | Common Stock | 2,918 | $61.18 | $179K | ||
| Option exercise | Common Stock | 2,284 | $64.25 | $147K | ||
| Option exercise | Common Stock | 2,709 | $61.76 | $167K | ||
| Option exercise | Common Stock | 3,148 | $68.62 | $216K | ||
| Option exercise | Common Stock | 2,072 | $71.93 | $149K | ||
| Option exercise | Common Stock | 9,459 | $72.27 | $684K | ||
| Option exercise | Common Stock | 2,623 | $74.78 | $196K | ||
| Open-market sale | Common Stock | 6,055 | $120.43 | $729K | ||
| Option exercise | Employee Stock Option (right to buy) | 2,918 | $0.00 | - | ||
| Option exercise | Employee Stock Option (right to buy) | 2,284 | $0.00 | - | ||
| Option exercise | Employee Stock Option (right to buy) | 2,709 | $0.00 | - | ||
| Option exercise | Employee Stock Option (right to buy) | 3,148 | $0.00 | - | ||
| Option exercise | Employee Stock Option (right to buy) | 2,072 | $0.00 | - | ||
| Option exercise | Employee Stock Option (right to buy) | 9,459 | $0.00 | - | ||
| Option exercise | Employee Stock Option (right to buy) | 2,623 | $0.00 | - | ||
| Option exercise | Employee Stock Option (right to buy) | 2,864 | $0.00 | - | ||
| Option exercise | Employee Stock Option (right to buy) | 1,643 | $0.00 | - | ||
| Option exercise | Employee Stock Option (right to buy) | 3,023 | $0.00 | - | ||
| Option exercise | Employee Stock Option (right to buy) | 2,623 | $0.00 | - | ||
| Option exercise | Employee Stock Option (right to buy) | 1,642 | $0.00 | - | ||
| Option exercise | Employee Stock Option (right to buy) | 2,293 | $0.00 | - | ||
| Option exercise | Employee Stock Option (right to buy) | 85 | $0.00 | - | ||
| Option exercise | Employee Stock Option (right to buy) | 326 | $0.00 | - | ||
| Option exercise | Employee Stock Option (right to buy) | 6,055 | $0.00 | - | ||
| Michael James Morrissey - Officer | Grant or award | Employee Stock Option (right to buy) | 6,426 | $0.00 | - | |
| Michael James Morrissey - Officer | Grant or award | Performance Shares | 8,999 | $0.00 | - | |
| Lee Heeson - Officer | Grant or award | Employee Stock Option (right to buy) | 15,423 | $0.00 | - | |
| Lee Heeson - Officer | Grant or award | Performance Shares | 13,498 | $0.00 | - | |
| Thomas Tray - Officer | Grant or award | Common Stock | 2,834 footnote F1 | $0.00 | - | |
| Thomas Tray - Officer | Grant or award | Employee Stock Option (right to buy) | 4,079 | $0.00 | - | |
| ||||||
| Steven H. Stein - Officer | Open-market sale | Common Stock | 1,877 | $114.73 | $215K | |
| Steven H. Stein - Officer | Grant or award | Common Stock | 9,798 footnote F1 | $0.00 | - | |
| Steven H. Stein - Officer | Grant or award | Performance Shares | 24,496 | $0.00 | - | |
| Steven H. Stein - Officer | Grant or award | Employee Stock Option (right to buy) | 42,298 | $0.00 | - | |
| ||||||
| Grant or award | Common Stock | 5,916 footnote F1 | $0.00 | - | ||
| Grant or award | Performance Shares | 14,790 | $0.00 | - | ||
| Grant or award | Employee Stock Option (right to buy) | 25,538 | $0.00 | - | ||
| ||||||
| Grant or award | Common Stock | 13,403 footnote F1 | $0.00 | - | ||
| Grant or award | Performance Shares | 33,508 | $0.00 | - | ||
| Grant or award | Employee Stock Option (right to buy) | 57,861 | $0.00 | - | ||
| ||||||
| Mohamed Khairie Issa - Officer | Open-market sale | Common Stock | 1,093 | $115.01 | $126K | |
| Mohamed Khairie Issa - Officer | Grant or award | Common Stock | 7,857 footnote F1 | $0.00 | - | |
| Mohamed Khairie Issa - Officer | Grant or award | Performance Shares | 19,643 | $0.00 | - | |
| Mohamed Khairie Issa - Officer | Grant or award | Employee Stock Option (right to buy) | 33,918 | $0.00 | - | |
| ||||||
| Ramitpal K. Basi - Officer | Grant or award | Common Stock | 4,991 footnote F1 | $0.00 | - | |
| Ramitpal K. Basi - Officer | Grant or award | Performance Shares | 12,479 | $0.00 | - | |
| Ramitpal K. Basi - Officer | Grant or award | Employee Stock Option (right to buy) | 21,548 | $0.00 | - | |
| ||||||
| David H. Gardner - Officer | Grant or award | Common Stock | 7,395 footnote F1 | $0.00 | - | |
| David H. Gardner - Officer | Grant or award | Performance Shares | 18,487 | $0.00 | - | |
| David H. Gardner - Officer | Grant or award | Employee Stock Option (right to buy) | 31,923 | $0.00 | - | |
| ||||||
| Richard A. Hoffman - Officer | Grant or award | Common Stock | 7,395 footnote F1 | $0.00 | - | |
| Richard A. Hoffman - Officer | Grant or award | Performance Shares | 18,487 | $0.00 | - | |
| Richard A. Hoffman - Officer | Grant or award | Employee Stock Option (right to buy) | 31,923 | $0.00 | - | |
| ||||||
| William Meury - Officer | Grant or award | Common Stock | 26,807 footnote F1 | $0.00 | - | |
| William Meury - Officer | Grant or award | Performance Shares | 80,421 | $0.00 | - | |
| William Meury - Officer | Grant or award | Employee Stock Option (right to buy) | 77,148 | $0.00 | - | |
| ||||||
| Tax withholding / forfeiture | Common Stock | 17,969 footnote F1 | $114.88 | $2.06M | ||
| Tax withholding / forfeiture | Common Stock | 4,950 footnote F1 | $115.09 | $570K | ||
| ||||||
| Tax withholding / forfeiture | Common Stock | 437 footnote F1 | $114.88 | $50K | ||
| Tax withholding / forfeiture | Common Stock | 1,512 footnote F1 | $115.09 | $174K | ||
| ||||||
| Thomas Tray - Officer | Tax withholding / forfeiture | Common Stock | 692 footnote F1 | $114.88 | $79K | |
| Thomas Tray - Officer | Tax withholding / forfeiture | Common Stock | 1,098 footnote F1 | $115.09 | $126K | |
| ||||||
| Steven H. Stein - Officer | Open-market sale | Common Stock | 28,237 | $113.05 | $3.19M | |
| Steven H. Stein - Officer | Tax withholding / forfeiture | Common Stock | 21,830 footnote F1 | $114.88 | $2.51M | |
| Steven H. Stein - Officer | Tax withholding / forfeiture | Common Stock | 3,088 footnote F1 | $115.09 | $355K | |
| ||||||
| Mohamed Khairie Issa - Officer | Tax withholding / forfeiture | Common Stock | 1,099 footnote F1 | $115.09 | $126K | |
| ||||||
| Tax withholding / forfeiture | Common Stock | 350 footnote F1 | $116.86 | $41K | ||
| ||||||
Recent INCY Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| PABLO CAGNONI | Officer | 23,218 | $2.80M | View on EDGAR | |
| PABLO CAGNONI | Officer | 10,801 | $1.36M |
INCY insider trading FAQ
What is the latest insider trade for INCY?
INCYTE CORP (INCY) had 24 insider filings in the last 90 days, with the most recent on 2026-10-05. The full record for INCY runs to 139 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying INCY stock?
No insider purchases of INCY were filed in the last 90 days.
How many insiders are selling INCY stock?
21 insider sales of INCY were filed in the last 90 days, totaling $15.01M.
Where can I see INCY SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects INCY Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Lee Heeson view on EDGAR
- - BAKER BROS. ADVISORS LP view on EDGAR
- - Paul J. Clancy view on EDGAR
- - Edmund Harrigan view on EDGAR
- - David H. Gardner view on EDGAR
- - Pablo J. Cagnoni view on EDGAR
- - Ramitpal K. Basi view on EDGAR
- - Pablo J. Cagnoni view on EDGAR
- - Pablo J. Cagnoni view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where INCY's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow INCY with a 7-day demo
- INCY on your watchlist
- Every INCY Form 4 filing on record
- Up to 3 months of INCY price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive